CCL2 and neoplasm: Tumour-specific blood immune features were also identified, with elevated levels of G-CSF, IL-6 and CXCL13, and B cell counts associating with prediction of 4T1 growth, while blood CCL17, CXCL10, CXCL1, total myeloid cells, CCL2, Ly6Cintermediate monocytes, and IL-10 levels were involved with predicting CT26 tumour growth.